Expertsʼ Opinion on the Prenatal Therapy of Congenital Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency – Guideline of DGKED ^{in cooperation with DGGG (S1-Level, AWMF Registry No. 174/013, July 2015)}

Abstract

Purpose: This guideline of the German Society of Pediatric Endocrinology and Diabetology (DGKED) is designed to be expertsʼ opinion on the current concept of prenatal therapy for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH). Several scientific medical societies have also participated in the guideline. It aims to offer guidance to physicians when they counsel affected families about prenatal therapy. Methods: The experts commissioned by the medical societies developed a consensus in an informal process. The consensus was subsequently confirmed by the steering committees of the respective medical societies. Recommendations: Prenatal CAH therapy is an experimental therapy. We recommend designing and using standardized protocols for the prenatal diagnosis, therapy and long-term follow-up of women and children treated prenatally with dexamethasone. If long-term follow-up is not possible, then prenatal therapy should not be performed.

I Information on the Guideline

Guidelines program

Information on the guidelines program is available at the end of the guideline.

Citation format

Expertsʼ Opinion on the Prenatal Therapy of Congenital Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Defiency – Guideline of DGKED in cooperation with DGGG (S1-Level, AWMF Registry No. 174/013, July 2015) Geburtsh Frauenheilk 2015; 75: 1232–1238

Guideline documents

The complete long version of this guideline and of the guideline report with a summary of the conflicts of interests of all authors plus PDF slide set suitable for PowerPoint presentations are available in German on the homepage of the AWMF: http://www.awmf.org/leitlinien/detail/ll/174-013.html

Authors

See Table 1.

Table 1 Authors.

AuthorMandate holder	Medical society/organization/association
Coordinating lead guideline author
Prof. Dr. Helmuth-Günther Dörr	German Society of Pediatric Endocrinology and Diabetology (Deutsche Gesellschaft für Kinderendokrinologie und -diabetologie e. V. [DGKED])
Other lead guideline authors
Prof. Dr. Gerhard Binder	German Society of Pediatric Endocrinology and Diabetology (Deutsche Gesellschaft für Kinderendokrinologie und -diabetologie e. V. [DGKED])
PD Dr. Nicole Reisch	German Society of Endocrinology (Deutsche Gesellschaft für Endokrinologie e. V. [DGE])
Prof. Dr. Ulrich Gembruch	German Society of Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. [DGGG])
PD Dr. Patricia G. Oppelt	Pediatric and Adolescent Gynecology Working Group (AG Kinder- und Jugendgynäkologie e. V.)
Prof. Dr. Peter Wieacker	German Society of Human Genetics (Deutsche Gesellschaft für Humangenetik e. V. [GfH])
Prof. Dr. Jürgen Kratzsch	German Society for Clinical Chemistry and Laboratory Medicine (Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin [DGKL])
Guideline secretariat
Dr. Anja Moß	University Hospital for Pediatric and Adolescent Medicine, University of Ulm (Universitätsklinik für Kinder- und Jugendmedizin, Universität Ulm)

Abbreviations

BW body

weight

CAH congenital

adrenal hyperplasia

cffDNA cell-free

fetal DNA

CVS chorionic

villus sampling

DHEAS dehydroepiandrosterone

sulfate

GW week

of gestation

NIPT non-invasive

prenatal testing

II Application of the Guideline

Purpose and objectives

Prenatal therapy of CAH has been a treatment option in Germany for many years, although it remains an experimental treatment. The medical societies involved in this guideline have not previously released any official statements regulating this therapy or the follow-up of treated patients. Internationally, increasing numbers of comments have been published opposing this therapy. The aim of this guideline is to provide guidance to physicians when making decisions and to improve the counseling on prenatal therapy offered to affected families.

Targeted areas of patient care

Physicians working in private (outpatient) practice or in specialized hospitals.

Target audience

The target audience for this guideline are physicians working in the specialties such as genetics, gynecology, obstetrics, internal medicine and pediatric endocrinology.

Targeted patient group: planned pregnancy in families with one child with classic CAH (index case), heterozygous and homozygous carriers for classic CAH, and compound heterozygous carriers for non-classic CAH.

Period of validity

The validity of this guideline was confirmed by the boards/responsible persons of the participating medical societies/working groups/organizations/associations as well as by the board of the DGGG and the DGGG Guideline Commission in July 2015 and thereby approved in its entirety. This guideline is valid from July 1, 2015 to July 1, 2016. The period of validity has been estimated based on the guidelineʼs contents.

III Guideline

1 Methodology

The guideline was registered with AWMF on September 1, 2013. Professors Dörr and Binder compiled an initial draft of the guideline based on the consensus of the guideline group and sent the draft by e-mail to all persons involved. Drafts were circulated by e-mail between all authors and revised until the group reached a consensus.

Use of existing guidelines on the same topic

Existing guidelines AWMF Registry numbers 027/022, 027/047 and 078/015 which contain material relevant to the topic under discussion were consulted during the compilation of this guideline.

External review and adoption

A version of the S1-guideline was placed online (on the homepage of DGKED) for public consultation for a period of 5 weeks (13.05.2014 – 16.06.2014) and the members of the involved medical societies were informed. Comments were collected and processed by the guideline group. Changes to the text of the guideline were done based on consensus. Everyone who sent in a comment was informed about the procedures used to process comments. The guideline group and the board of the DGKED approved the final version of the guideline in September 2014. This was followed by the final adoption of the guideline by the boards of the involved medical societies/organizations. During this procedure the board of Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ) withdrew its mandate and did not approve the final version of the guideline. Despite several discussions to clarify the issues, it proved impossible to obtain the approval of the DGKJ. The boards of the other 5 medical societies involved were then informed about the circumstances, and the importance and necessity of having an S1 recommendation for action in the current form was emphasized. The positive responses of the 5 other medical societies were filed with the secretariat of the DGKED by July 1, 2015. The final version of the guideline was submitted to AWMF on July 2, 2015.

2 Introduction

The authors are well aware that it is impossible to create an evidence-based guideline for a non-approved therapy. This S1-guideline therefore represents an opinion; the guideline summarizes the current situation and offers recommendations for further action.

3 Preamble

Female neonates with classic congenital adrenal hyperplasia due to congenital deficiency of 21-hydroxylase (CAH) are usually born with intersex external genitalia. The therapy administered prenatally to treat CAH has the following aims: preventing the virilization of female fetuses with CAH; preventing corrective genital surgery; and avoiding psychosocial stress for the family when their daughter is born with intersex genitalia. Complex genitoplasty procedures have their own surgery-related problems and are also associated with psychosocial stress for the affected patient and family.

As the differentiation of female genitalia starts in the 7th week after conception, therapy must be initiated immediately after establishing pregnancy. As no prenatal diagnosis is possible at this point in time, all pregnancies at risk for CAH are initially treated without knowing the diagnosis. The drug of choice is dexamethasone, which cannot be metabolized by the placenta and therefore achieves a maternal-fetal gradient of 1 : 1. Dexamethasone is administered immediately after the pregnancy has been established to women who have an increased risk of giving birth to a child with classic CAH. Therapy is only continued until the end of pregnancy if the prenatal diagnosis shows that the child is female and has classic CAH. In all other cases prenatal therapy is terminated.

The use of dexamethasone for the prenatal therapy of CAH is an off-label use. Nevertheless, this experimental therapy has been used all over the world for almost 30 years. The results published to date show that prenatal therapy – if it is administered correctly – can prevent virilization of the external genitalia in females 1, 2, 3, 4, 5. The therapy is controversial because of the ethical dilemma (unaffected children are also treated) and because some data have shown that the therapy may have negative emotional and cognitive consequences. These data are from studies with small case numbers. Larger studies are therefore urgently required, along with follow-up examinations of all children treated prenatally, to determine or exclude possible side effects such as fetal programming from prenatal dexamethasone. The therapy requires the close cooperation of all involved physicians, particularly between prenatal medical centers and human genetics departments. Written parental consent is required after the physician has had an in-depth talk with the parents. Only gynecologists working closely with gynecology and/or internal endocrinology departments and certified prenatal medical centers can offer the appropriate care to the pregnant mother.

There is currently no standardized evidence-based protocol for the prenatal therapy of fetuses with CAH in Germany. The recommendations for prenatal therapy are based on empirical experience and data obtained from the literature. A careful and detailed documentation of the administered prenatal therapy should be a matter of course. In addition, it will be necessary to develop and implement protocols to follow-up children treated prenatally and their mothers.

4 Definition and Basic Information

(See also the guidelines with AWMF registry numbers 027/022, 027/047 and 078/015)

Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CYP21A2) is the most common disorder of cortisol biosynthesis in the adrenal cortex, with a prevalence of more than 90 %. The inheritance pattern for this disorder is autosomal recessive; the CYP21A2 gene is located on the short arm of chromosome 6 in the HLA III region in close proximity to a highly homologous pseudogene. Depending on the severity of the genetic defect and the extent of residual 21-hydroxylase activity, CAH occurs in one of 2 forms: classic CAH and non-classic CAH 6.

Female newborns with classic CAH present with intersex external genitalia (disorder of genital differentiation but normal female karyotype) at birth. Virilization of genitalia already starts in utero. The inner genitalia are always female, i.e. a uterus and ovaries are present. The severity of virilization is classified using the Prader scale and ranges from simple clitoral hypertrophy (Prader score 1) to complete fusion of the labioscrotal folds, an enlarged phallus-like clitoris, and extension of the urethra with a urethral opening in the glans penis (Prader score 5). Genital corrective surgery is often considered for girls with intersex genitalia (Prader score 3 and higher).

Female neonates born with non-classic CAH are unremarkable at delivery; while still prepubescent they may sometimes present with premature pubarche and/or acne. During puberty and after the conclusion of puberty girls with non-classic CAH are characterized by hyperandrogenemia, disorders of the menstrual cycle, and infertility.

5 Diagnosis

5.1 Prior to pregnancy

Affected families usually have an index case (a previous child with CAH). In rare cases parents may be known to be heterozygous without an index case. Detailed genetic counseling with genetic diagnosis of the index case and of the parents should be done prior to conception. An interdisciplinary consultation about the therapeutic options and the approach used in prenatal therapy should also be done prior to conception. Parents should be informed during a detailed consultation that in the case of autosomal recessive inheritance, both boys and girls have a 1 in 4 risk of developing CAH. It follows from the above that as long as the sex of the child is still unknown, 7 of 8 fetuses will be treated unnecessarily, i.e., 3 girls who do not require treatment and 4 boys who do not require treatment, as boys with CAH do not require treatment. The family must be informed of the benefits and the possible downsides (potential side effects for the mother and child; experience in animals and humans, long-term risks) of prenatal therapy as well as the risks involved in prenatal diagnosis.

The parents must also be informed of the fact that there is currently no standardized protocol for this treatment. There are also no protocols in Germany for the long-term follow-up care of children treated prenatally (or of their mothers), and treatment in Germany is currently based on protocols and data from other countries such as Sweden and the USA 1, 7.

All forms of genetic testing and the isolation of fetal DNA from maternal blood are diagnostic tests which are subject to the relevant provisions of the German Genetic Diagnosis Act.

Possible combinations of factors where prenatal therapy should be considered:

1. Families with one affected child (index case) with classic CAH (CYP21A2).

2. Known parental heterozygosity for classic CAH (no index case).

3. New relationship of a parent of a child with classic CAH if the new partner is known to be a carrier for classic CAH.

4. Homozygosity or compound heterozygosity for classic CAH of one parent when the other parent is a heterozygous gene carrier for classic CAH.

Genetic counseling is more difficult if the potential parents have differing mutations and there is no index case in the family with compound heterozygosity for these mutations.

Example: The mother has a typical mutation for classic CAH, while the father has a mutation for non-classic CAH (e.g. exon 7 Val281Leu). In this case the child could be compound heterozygous for CAH. The phenotype generally follows the mutation associated with higher residual activity, in other words, non-classic CAH. This means that in this family prenatal therapy is not indicated.

5.2 Prenatal diagnosis

The prenatal diagnosis of CAH is made based on an invasive procedure, typically chorionic villus sampling (CVS) performed approximately in the 11th week of gestation (GW). The childʼs sex is determined using genetic methods or chromosome analysis after cells are briefly cultured. In the event that testing finds a female karyotype, genetic testing is then used to investigate whether the expected child is homozygous/compound heterozygous or heterozygous or only has the wild-type allele. In principle, prenatal genetic diagnosis could be done as part of amniocentesis. But as amniocentesis is performed later in pregnancy (from the 14th GW), prenatal diagnosis using CVS is preferable as it ensures that the period of potentially unnecessary dexamethasone intake is as short as possible. The risk of miscarriage is 0.5–1 % for amniocentesis and approximately 1 % for chorionic villus sampling.

Recently, 2 independent studies showed that it is possible to determine the sex of the fetus using the SRY test 8 and that correct genotyping 9 using cell-free fetal DNA (cffDNA) from maternal blood was possible in pregnancies at risk for CAH. In the study by Tardy-Guidollet et al., the SRY test was positive from the 5th week of gestation (4 weeks + 5 days). This avoided prenatal therapy with dexamethasone in 68 % of male fetuses 8. In the study by New et al., the earliest time of diagnosis was the 6th week of gestation; based on the results of the diagnostic procedure, prenatal therapy was initiated even prior to the 9th week 9.

Non-invasive fetal sex determination using cffDNA is not yet a routine diagnostic procedure in Germany, but it is offered as part of NIPT (non-invasive prenatal testing) from the 7th GW after the last menstrual cycle as the percentage of fetal DNA in the free DNA present in maternal blood should be high enough by that point (around 10 %). The result is usually available within one week after obtaining the blood sample 10, 11.

6 Current Experimental Therapy

There is currently no standardized therapy protocol approved by the respective medical societies in Germany. As sexual differentiation starts early, from the 7th week after conception, therapy was usually initiated immediately after establishing the pregnancy and without yet knowing the diagnosis.

The drug of choice is the glucocorticoid dexamethasone, which is not metabolized by the placenta and which therefore achieves a maternal-fetal gradient of 1 : 1 12. The recommended starting dose of dexamethasone (suggested dosage calculation formula: 20 µg/kg BW/day) is divided into 3 individual doses administered over a period of 24 h 13, 14. This dosage was determined empirically; there are no controlled studies on the optimal dosage or duration of therapy.

Some studies have also reported achieving the same effect with low dexamethasone dosages 15. The physician should therefore select the lowest maternal dexamethasone dose that will ensure suppression of the fetal adrenal cortex.

Therapy is only continued if the fetus is female and has classic CAH. If the fetus is not a mutation carrier and is not heterozygous or male, then the current practice is to reduce the dexamethasone dose by 0.5 mg every 2nd day.

The care provided to a pregnant high-risk woman must be closely coordinated by her gynecologist with a prenatal medical and/or endocrinology center. To the best of our knowledge, the procedure followed up to now in Germany is as follows:

During pregnancy

Sampling of maternal serum (approx. 2 ml): determination of cortisol (to verify suppression of the maternal adrenal cortex) and determination of estriol (to verify suppression of the fetal adrenal cortex) at the start of therapy and then every 4 weeks until birth 16. The Swedish PREDEX protocol measures DHEAS prior to initiating therapy (6th GW after the last menstrual cycle) and then every 4 weeks until the 36th GW and measures estriol in gestational weeks 16–36 7. High-risk pregnancies are continually monitored and parameters (e.g. blood pressure, weight changes, urine tests) are recorded.

During birth and postpartum

The dexamethasone dose administered to the mother is gradually reduced postpartum by 0.5 mg every 2nd day. Contacting the pediatric endocrinologist is recommended to discuss further diagnostic procedures and therapies. It is not necessary to arrange for an immediate transfer of the neonate to a pediatric hospital.

In the neonate

Neonatal screening should be done on the 3rd day of life; in addition, venous blood samples should be collected to determine serum electrolyte levels, for blood gas analysis, and to determine 17-OHP, androstenedione and testosterone levels and renin concentrations. Hydrocortisone therapy should be initiated (12–15 mg/m² body surface; e.g. 2–1– 1 mg/day) together with Astonin H therapy (0.1 mg tablets; e.g. ½ – ¼ – ½). Postnatal genetic confirmation of the prenatal diagnosis should be attempted (possibly through umbilical cord blood sampling).

6.1 Maternal safety

There are numerous studies on prenatal therapy 2, 4, 7, 17, 18, 19, 20, 21, 22. The study group working with Maria New in New York has the most extensive experience 18, 20, 23, 24, 25. Maternal side effects such as increased weight gain and/or striae and edema have been reported in individual cases; these effects were found to be reversible after dexamethasone was discontinued. Neither arterial hypertension nor diabetes mellitus were noted during dexamethasone therapy 20, 26.

In a survey done by questionnaire of dexamethasone-treated mothers in the USA (n = 22), almost all of them (n = 20) were positive about the benefits of prenatal therapy, stating that they would undergo dexamethasone treatment again in a subsequent pregnancy 27. These results are in contrast to results reported from Sweden 28. Only 70 % of women (n = 23) surveyed by questionnaire were prepared to undergo prenatal therapy again in a subsequent pregnancy.

6.2 Fetal and pediatric safety

Length at birth, head circumference and birthweight were within normal ranges for all of the neonates who received prenatal therapy. To date, there have been no reports of malformations such as orofacial cleft. Postnatal growth of treated children was normal 26. The long-term data, collected with the help of questionnaires sent to the parents (174 children treated prenatally compared with 313 untreated children, age range: 1 month to 12 years), showed no differences in cognitive, social or psychomotor development 29. A follow-up study was done of 140 children aged between 5 and 12 years, 25 of whom were girls with CAH who had received prenatal treatment. The study showed that girls with CAH treated prenatally were less masculine in their behavior compared to girls with CAH who did not receive prenatal therapy 30. Using standardized neuropsychological tests, Hirvikoski et al. found deficits in verbal working memory in children with CAH treated prenatally 31. A meta-analysis of studies published to date found no significant differences in the behavior of prenatally treated children 32. A follow-up of female patients with CAH treated prenatally (n = 8) found a trend to cognitive deficits compared to a control group (n = 15), but the difference was not statistically significant 33. One study group in Warsaw also subsequently carried out neuropsychological examinations of a small number of girls treated prenatally (9 with CAH vs. 8 without CAH) and found that the girls with CAH treated prenatally performed better in all cognitive tests 34.

6.3 Dexamethasone in animal experiments

Malformations such as orofacial clefts, pulmonary hypoplasia and anencephalus have been reported in experiments on animals treated with dexamethasone 22. Fatty degeneration of the liver (rats, sheep, primates) and changes in glomerular filtration rates have also been noted 35. There are also reports of disorders of brain development and behavioral changes in treated animals 36. Adult rodents had arterial hypertension and hyperglycemia with increased insulin concentrations after prenatal glucocorticoid therapy 37, 38. The offspring of non-human primates treated during pregnancy with high doses of dexamethasone (120 or 200 µg/kg BW per day) had increased cortisol levels after experiencing only mild stress as well as hypertension at the age of 12 months 39.

6.4 Documentation of prenatal therapy in Germany

Already in 1990, the working group/section for pediatric endocrinology (Arbeitsgemeinschaft/Sektion für Pädiatrische Endokrinologie [APE/SPE]) proposed that cases known to pediatric endocrinologists should be recorded in a central registry (Hospital for Children and Adolescents of Erlangen University, Prof. Dr. H.-G. Dörr). There was no plan to provide financial support for the project. A questionnaire was developed and initially sent to all pediatric endocrinologists based on the assumption that families (with an index case) would inform their pediatric endocrinologist of future pregnancies. The questionnaire was recently revised; one version was developed for the affected mother/family and another version was developed for the treating physician; the physiciansʼ version should be completed by the treating gynecologist. The questionnaires can be obtained from the homepages of DGKED (www.paediatrische-endokrinologie.de) and the German CAH self-help group (https://www.ags-initiative.de/) or are available on request.

Questionnaires are completed on a voluntary basis. It has not been possible to carry out any detailed analysis of the documented data in Germany as the questionnaires have either not been completed at all or were returned incomplete.

7 Conclusion and Prospects

Prenatal CAH therapy is still an experimental therapy. The experience to date has shown that prenatal therapy is effective. Female neonates with CAH who received prenatal therapy had externally unremarkable genitalia or genitalia with only mild virilization (Prader score 1). No serious maternal complications have been recorded; no malformations were reported for any of the neonates 40. Up to now, the ethical dilemma was that 7 of 8 fetuses (4 males and 3 females) were treated unnecessarily with dexamethasone. With new procedures for prenatal diagnosis based on an analysis of cell-free DNA obtained from maternal blood samples it will be possible in future to offer targeted therapy which will only treat female fetuses or even only homozygous or compound heterozygous female fetuses with CAH.

The data on the potential negative emotional and cognitive effects on children with CAH who received prenatal treatment must be taken seriously. However, these data are from studies with small case numbers. Larger studies and follow-up studies of all children treated prenatally are therefore urgently needed to establish or exclude side effects such as fetal programming from prenatal dexamethasone. Standardized protocols for prenatal diagnosis and therapy should be developed and implemented. This also applies to the long-term follow-up of women and children treated prenatally with dexamethasone. If long-term follow-up of the children cannot be guaranteed, then they should not be treated prenatally.

All prenatal CAH therapies should be documented and recorded in a central registry. The registry should also include those pregnancies where therapy was terminated early after receiving the results of the prenatal diagnostic procedure 6.

The medical societies involved should agree on a protocol for therapy and follow-up which should then be assessed and confirmed by an ethics committee.

Biography

Guideline Program. Editors: Leading Professional Medical Associations

German Society of Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. [DGGG]) Head Office of DGGG and Professional SocietiesHausvogteiplatz 12DE-10117 Berlin info@dggg.de http://www.dggg.de/

President of DGGG Prof. Dr. med. Diethelm WallwienerUniversitätsfrauenklinik TübingenCalwerstraße 7DE-72076 Tübingen

DGGG Guidelines Representative Prof. Dr. med. Matthias W. BeckmannUniversitätsklinikum ErlangenFrauenklinikUniversitätsstraße 21–23DE-91054 Erlangen

Guidelines Coordination Dr. med. Paul Gaß, Tobias Brodkorb, Marion GebhardtUniversitätsklinikum ErlangenFrauenklinikUniversitätsstraße 21–23DE-91054 Erlangen fk-dggg-leitlinien@uk-erlangen.de http://www.dggg.de/leitlinienstellungnahmen  

Austrian Society of Gynecology and Obstetrics (Österreichische Gesellschaft für Gynäkologie und Geburtshilfe [OEGGG]) Innrain 66AAT-6020 Innsbruck stephanie.leutgeb@oeggg.at http://www.oeggg.at

President of OEGGG Prof. Dr. med. Uwe LangUniversitätsklinik für Frauenheilkunde und Geburtshilfe GrazAuenbruggerplatz 14AT-8036 Graz

OEGGG Guidelines Representative Prof. Dr. med. Karl TamussinoUniversitätsklinik für Frauenheilkunde und Geburtshilfe GrazAuenbruggerplatz 14AT-8036 Graz 

Swiss Society of Gynecology and Obstetrics (Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [SGGG]) Gynécologie Suisse SGGGAltenbergstraße 29Postfach 6CH-3000 Bern 8 sekretariat@sggg.ch http://www.sggg.ch/

President of SGGG Dr. med. David EhmFMH für Geburtshilfe und GynäkologieNägeligasse 13CH-3011 Bern

SGGG Guidelines Representative Prof. Dr. med. Daniel SurbekUniversitätsklinik für FrauenheilkundeGeburtshilfe und feto-maternale MedizinInselspital BernEffingerstraße 102CH-3010 Bern